Business
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
- Fourth quarter 2025 GAAP total revenues of $284 million and full year 2025 GAAP total revenues of $1.07 billion, reflecting 9% and 12% year-over-year
About this update from Acadia Pharmaceuticals Inc.
[{"type":"text","content":"\n- Fourth quarter 2025 GAAP total revenues of $284 million and full year 2025 GAAP total revenues of $1.07 billion, reflecting 9% and 12% year-over-year growth, respectively\n\n\n- Fourth quarter 2025 non-GAAP adjusted total revenues of $298 million and full year 2025 non-GAAP adjusted total revenues of $1.08 billion, reflecting 16% and 14% year-over-year growth, respectively\n\n\n- Fourth quarter 2025 NUPLAZID® GAAP net sales of $174 million, including a non-recurring IRA rebate accrual change in estimate; Fourth quarter non-GAAP NUPLAZID net sales of $189 million\n\n\n- Fourth quarter 2025 DAYBUE ® GAAP net sales of $110 million, reflecting 13% year-over-year growth\n\n\n- Full year 2026 guidance for total revenues of $1.22 to $1.28 billion, including NUPLAZID net sales of $760 to $790 million and DAYBUE net sales of $460 to $490 million\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nAcadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the fourth quarter and full year ended December 31, 2025.\n\n\n“Acadia closed 2025 with another strong quarter, capping a milestone year in which we surpassed $1 billion in annual revenue for the first time,” said Catherine Owen Adams, Chief Executive Officer. “NUPLAZID had another strong quarter driven by underlying volume growth, reflecting continued momentum in the business. In the fourth quarter we received our first Inflation Reduction Act invoices for NUPLAZID inflation cap rebates, which resulted in NUPLAZID delivering GAAP net product sales of $174 million and non-GAAP adjusted net product sales of $189 million. DAYBUE generated $110 million in fourth‑quarter net product sales, driven by expanding reach in the community and continued contribution from named patient supply programs outside the U.S. We are seeing growing interest in our new DAYBUE STIX powder formulation as we prepare for a full launch in early Q2 of this year. We continue to advance a deep and differentiated R&D pipeline, anchored by remlifanserin, with the Phase 2 RADIANT study in Alzheimer’s disease psychosis serving as an important upcoming potential catalyst with top‑line results expected between August and October 2026.”\n\n\nCompany Updates\n\n\n\nCompletion of a strategic expansion of NUPLAZID customer‑facing teams, with a 30% increase in representatives, implemented in early 2026 and now ful...